Standard BioTools 3Q 2026: Revenue $19.4M, Net income $13.5M, EPS $0.03— 10-Q Summary

What happened

Standard BioTools reported third-quarter 2026 revenue of $19.4M, down 0.9% from $19.6M a year earlier. Net income was $13.5M, helped by $28.5M from discontinued operations, and diluted EPS was $0.03.

Confirmed

Global impact / market context

The profit came largely from selling businesses, not from ongoing sales, which slightly declined. Instrument sales rose 18%, but lower consumables and service revenue offset that gain, so investors should judge future results on continuing operations rather than one-time income.

Analyst inference

The company is shrinking through divestitures: the SomaScan sale closed, and it plans to sell its mass cytometry and microfluidics businesses ahead of a Treeline merger vote on November 19. Cost cuts in Singapore support cash until closing.

Analyst inference

What to watch

1. The Treeline merger registration statement became effective October 21, 2026, with a stockholder vote scheduled for November 19 and closing expected in the fourth quarter. Confirmed
2. The company plans to sell its mass cytometry business to Element Biosystems and its microfluidics business to ARCHIMED, so completion timing and terms matter for future revenue. Proposed
3. Consumables, the recurring sales tied to instruments already in use, grew 5% over nine months while instruments fell 8%, so watch whether that recurring base stabilizes. Analyst inference

Evidence

• Original source link unavailable